Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus
Yıl: 2022 Cilt: 54 Sayı: 2 Sayfa Aralığı: 197 - 201 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.22128 İndeks Tarihi: 05-07-2022
Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus
Öz: Objective: In the present study, the relationship between a poor prognosis and adropin levels in diabetic
patients with coronavirus disease 2019 was investigated by measuring serum adropin levels and levels of
D-dimer, C-reactive protein, and ferritin, which are considered prognostic factors for coronavirus disease
2019.
Materials and Methods: Hundred volunteer participants treated in the Erzurum Regional Training and
Research Hospital were included in this study. Serum adropin levels were measured by enzyme-linked
immunosorbent
assay. The relationship between serum adropin level and C-reactive protein, ferritin, and
D-dimer levels was analyzed by correlation analysis.
Results: The participants’ serum adropin levels differed between the groups (P = .0007). The control group
had the highest adropin levels among groups. The lowest adropin levels were in the COVID + diabetes mellitus
group. Adropin levels of diabetes mellitus, COVID, and diabetes mellitus + COVID groups were significantly
decreased when compared to the control (P < .05). There was a significant negative correlation
between adropin and C-reactive protein, D-dimer, and ferritin.
Conclusion: Adropin can be used as an auxiliary biomarker, a prognostic factor in the early management of
coronavirus disease 2019 patients with diabetes mellitus. We think that our study will guide future studies
conducted in this field.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-Ncov: prevalence, biological and clinical characteristics comparison with SARS-Cov and MERS-Cov. Eur Rev Med Pharmacol Sci. 2020;24(4):2012-2019. [CrossRef]
- 2. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368(March):m1036. [CrossRef]
- 3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497- 506. [CrossRef]
- 4. Harcourt J, Tamin A, Lu X, et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg Infect Dis. 2020;26(6):1266-1273. [CrossRef]
- 5. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. [CrossRef]
- 6. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID- 19 in China. Clin Res Cardiol. 2020;109(5):531- 538. [CrossRef]
- 7. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-Cov-2. J Endocrinol Invest. 2020;43(6):867-869. [CrossRef]
- 8. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195-2198. [CrossRef]
- 9. Piva S, Filippini M, Turla F, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection in Brescia, Italy. J Crit Care. 2020;58:29-33. [CrossRef]
- 10. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. [CrossRef]
- 11. Fang C, Huang Y, Guo H, et al. Mechanism of higher risk for COVID-19 in diabetes: a mask to lift. Endocrine. 2020;69(3):477-480. [CrossRef]
- 12. Codo AC, et al. Elevated glucose levels favor SARS-Cov-2 infection and monocyte response Through a HIF-1 α/gly colys is-de pende nt axis. Cell Metab. 2020;32(3):437-446.E5.
- 13. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-481. [CrossRef]
- 14. Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a fat-burning hormone with multiple functions-review of a decade of research. Molecules. 2020;25(3). [CrossRef]
- 15. Maciorkowska M, Musiałowska D, Małyszko J. Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Adv Clin Exp Med. 2019;28(11):1571-1575. [CrossRef]
- 16. Ye Z, Zhang C, Zhao Y. Potential effects of adropin on systemic metabolic and hormonal abnormalities in polycystic ovary syndrome. Reprod Biomed Online. 2021;42(5):1007-1014. [CrossRef]
- 17. Yosaee S, Khodadost M, Esteghamati A, et al. Metabolic syndrome patients have lower levels of adropin when compared with healthy overweight/ obese and lean subjects. Am J Mens Health. 2017;11(2):426-434. [CrossRef]
- 18. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751-758. [CrossRef]
- 19. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11):S185-S192. [CrossRef]
- 20. Oruc CU, Akpinar YE, Dervisoglu E, et al. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flowmediated dilatation in patients with metabolic syndrome. Clin Chem Lab Med (CCLM). 2017;55(1):139-144. [CrossRef]
- 21. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161-1164. [CrossRef]
- 22. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-792. [CrossRef]
- 23. Zhang S, Chen Q, Lin X, Chen M, Liu Q. A review of adropin as the medium of dialogue between energy regulation and immune regulation. Oxid Med Cell Longev. 2020;2020:3947806. [CrossRef]
- 24. Sato K, Yamashita T, Shirai R, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci. 2018;19(5):1293. [CrossRef]
- 25. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the working group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(2):233-246. [CrossRef]
- 26. Centers for Disease Control and Prevention (U.S.). COVID-19 response team, preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386.
- 27. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406- 418. [CrossRef]
- 28. Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with coronavirus 2019. Clin Infect Dis. 2020;71(16):2174-2179. [CrossRef]
- 29. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-334. [CrossRef]
- 30. Düz ME, Balcı A, Menekşe E. D-dimer levels and COVID-19 severity: systematic review and meta-analysis. Tuberk Toraks. 2020;68(4):353- 360. [CrossRef]
- 31. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219-225. [CrossRef]
- 32. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020;34(10):e23618. [CrossRef]
| APA | Aydın P, KARABULUT UZUNÇAKMAK S, Tor I, Bilen A, OZDEN A (2022). Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. , 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| Chicago | Aydın Pelin,KARABULUT UZUNÇAKMAK SEVGİ,Tor Ibrahim Hakki,Bilen Arzu,OZDEN AYSE Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. (2022): 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| MLA | Aydın Pelin,KARABULUT UZUNÇAKMAK SEVGİ,Tor Ibrahim Hakki,Bilen Arzu,OZDEN AYSE Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. , 2022, ss.197 - 201. 10.5152/eurasianjmed.2022.22128 |
| AMA | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. . 2022; 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| Vancouver | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. . 2022; 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| IEEE | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A "Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus." , ss.197 - 201, 2022. 10.5152/eurasianjmed.2022.22128 |
| ISNAD | Aydın, Pelin vd. "Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus". (2022), 197-201. https://doi.org/10.5152/eurasianjmed.2022.22128 |
| APA | Aydın P, KARABULUT UZUNÇAKMAK S, Tor I, Bilen A, OZDEN A (2022). Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. Eurasian Journal of Medicine, 54(2), 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| Chicago | Aydın Pelin,KARABULUT UZUNÇAKMAK SEVGİ,Tor Ibrahim Hakki,Bilen Arzu,OZDEN AYSE Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. Eurasian Journal of Medicine 54, no.2 (2022): 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| MLA | Aydın Pelin,KARABULUT UZUNÇAKMAK SEVGİ,Tor Ibrahim Hakki,Bilen Arzu,OZDEN AYSE Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. Eurasian Journal of Medicine, vol.54, no.2, 2022, ss.197 - 201. 10.5152/eurasianjmed.2022.22128 |
| AMA | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. Eurasian Journal of Medicine. 2022; 54(2): 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| Vancouver | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus. Eurasian Journal of Medicine. 2022; 54(2): 197 - 201. 10.5152/eurasianjmed.2022.22128 |
| IEEE | Aydın P,KARABULUT UZUNÇAKMAK S,Tor I,Bilen A,OZDEN A "Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus." Eurasian Journal of Medicine, 54, ss.197 - 201, 2022. 10.5152/eurasianjmed.2022.22128 |
| ISNAD | Aydın, Pelin vd. "Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus". Eurasian Journal of Medicine 54/2 (2022), 197-201. https://doi.org/10.5152/eurasianjmed.2022.22128 |
